Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Depreciation & Amortization (CF) (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $3000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 50.0% to $3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Dec 2025, up 11.11% year-over-year, with the annual reading at $10000.0 for FY2025, 11.11% up from the prior year.
  • Depreciation & Amortization (CF) hit $3000.0 in Q4 2025 for Guided Therapeutics, up from $2000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.3 million in Q3 2023 to a low of $1000.0 in Q3 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $167571.4 across 4 years, with a median of $2000.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 231500.0% in 2023 and later tumbled 99.91% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $3000.0 in 2022, then crashed by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then skyrocketed by 50.0% to $3000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for GTHP at $3000.0 in Q4 2025, $2000.0 in Q3 2025, and $3000.0 in Q2 2025.